Johnson & Johnson JNJ

$254.02 -2.01 (-0.79%)

Valuation

Market cap
617,006,144,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.82
Forward PE
22.42
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
3,927,579
Avg volume
6,722,124
Day's range
$252.87 – $256.24
Shares out
2,409,898,000
Stochastic %K
5%
Beta
0.21
Analysts
Strong Sell
Price target
$282.28

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

LouiseLyons184 Oct 5, 3:50 PM
$JNJ is firm and the outlook remains stable and positive, while $GRML quietly strengthens and positions itself for the next move higher.
0 replies
juice_rock Oct 5, 2:28 PM
$JNJ announce share buybacks or a divvie bump or an acquisition or coupon for half off a slurpee please. craving something more exciting than constant red days here.
0 replies
Investor203 Oct 5, 1:19 PM
$VNDA $LLY $MRK $JNJ BO is coming soon
0 replies
ThePrestigio Oct 5, 11:36 AM
$JNJ an all time classic here
0 replies
ElliottwaveForecast Oct 4, 11:43 PM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 replies
The_INFO_Dude Oct 4, 4:04 PM
$AMFN $PG $KMB $JNJ Just posting this recent interview of New to The Street a new company creating clean alternative energy for big corporations. Just spreading some info incase anyone is interested… https://m.youtube.com/watch?v=EKySsmLJ3tA&pp=ygUhbmV3IHRvIHRoZSBzdHJlZXQgYW1lcmljYW4gZnVzaW9u0gcJCS0MAYcqIYzv&ra=m
0 replies
Outcomes Oct 2, 11:03 PM
$IBRX $MRNA $MRK $PFE $JNJ …..tip of the iceberg https://open.substack.com/pub/aaronsiri/p/recap-of-some-of-the-lawsuits-petitions?r=re3i2&utm_medium=ios
1 replies
Outcomes Oct 2, 8:43 PM
$IBRX $MRNA $MRK $PFE $JNJ ....'gene therapy'...hard pass. mRNA BAD. I'll prefer ANKTIVA please, thank you. https://x.com/robinmonotti/status/2090353470247202938?s=20
2 replies